Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase II, Randomized, Double-blind, Placebo-controlled Multicenter Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Efficacy of CS0159 in the Treatment of Patients With Nonalcoholic Steatohepatitis (NASH)

NCT05591079 is registered in ClinicalTrials.gov with Cascade Pharmaceuticals, Inc as lead sponsor.

NCT NCT05591079
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT05591079 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase II, Randomized, Double-blind, Placebo-controlled Multicenter Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Efficacy of CS0159 in the Treatment of Patients With Nonalcoholic Steatohepatitis (NASH)
Lead sponsor
Cascade Pharmaceuticals, Inc
Phase
Phase 2
Overall status
Completed
Start date
February 10, 2023
Completion date
November 9, 2023
Enrollment
99 (actual)
Sites
17

Conditions

As the registry lists them; a condition with its own page is linked.

nonalcoholic steatohepatitis (nash)